Catamaran Bio: Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT-179, a HER2-targeted Allogeneic CAR-NK Cell Therapy

- CAT-179 significantly reduces tumor burden and extends survival in a mouse HER2+ xenograft model - BOSTON--(BUSINESS WIRE)-- Catamaran Bio, Inc., a biotechnology company developing allogene...